1996至2016年美国呼吸系统疾病医疗支出分析
该研究基于美国健康指标与评估研究所疾病支出项目数据库,估算1996至2016年11种呼吸系统疾病的医疗支出。哮喘和慢阻肺支出最高。服务价格与强度增长与81.4%的支出增长相关。
要点
- 服务价格与强度增长与1996至2016年81.4%的支出增长相关
核心结论
- 美国呼吸系统疾病医疗支出高,尤其是哮喘和慢阻肺等慢性疾病。
- 服务价格与强度(尤其是药品)应成为政策制定者控制支出增长的重点。
研究设计与样本
- 研究提取健康指标与评估研究所疾病支出项目数据库数据,生成38个年龄和性别组、7种照护类型、3种支付方类型的年度支出估算。
- 采用分解分析评估五种因素(人口增长、人口老龄化、疾病患病率、服务使用、服务价格与强度)与支出变化的关系。
主要发现
- 服务价格与强度增加与1996至2016年81.4%(95%CI 70.3-93.0%)的支出增长相关。
临床怎么用
- 提示临床医生关注哮喘和慢阻肺等慢性呼吸系统疾病带来的高医疗支出。
- 政策制定者可重点关注服务价格与强度(尤其是药品)以控制支出增长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Respiratory conditions account for a large proportion of health care spending in the United States. A full characterization of spending across multiple conditions and over time has not been performed. Objectives: To estimate health care spending in the United States for 11 respiratory conditions from 1996 to 2016, providing detailed trends and an evaluation of factors associated with spending growth. Methods: We extracted data from the Institute of Health Metrics and Evaluation's Disease Expenditure Project Database, producing annual estimates in spending for 38 age and sex groups, 7 types of care, and 3 payer types. We performed a decomposition analysis to estimate the change in spending associated with changes in each of five factors (population growth, population aging, disease prevalence, service usage, and service price and intensity). Measurements and Main Results: Total spending across all respiratory conditions in 2016 was $170.8 billion (95% confidence interval [CI], $164.2-179.2 billion), increasing by $71.7 billion (95% CI, $63.2-80.8 billion) from 1996. The respiratory conditions with the highest spending in 2016 were asthma and chronic obstructive pulmonary disease, contributing $35.5 billion (95% CI, $32.4-38.2 billion) and $34.3 billion (95% CI, $31.5-37.3 billion), respectively. Increasing service price and intensity were associated with 81.4% (95% CI, 70.3-93.0%) growth from 1996 to 2016. Conclusions: U.S. spending on respiratory conditions is high, particularly for chronic conditions like asthma and chronic obstructive pulmonary disease. Our findings suggest that service price and intensity, particularly for pharmaceuticals, should be a key focus of attention for policymakers seeking to reduce health care spending growth.
引用
- Duan KI, Birger M, Au DH, et al. Health Care Spending on Respiratory Diseases in the United States, 1996-2016. Am J Respir Crit Care Med. 2023. PMID: 35997678. doi:10.1164/rccm.202202-0294OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。